Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180720
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Maristany Bosch, Marta | - |
dc.contributor.author | Cuervo Requena, Guillermo | - |
dc.contributor.author | Matas Martín, Elisabet | - |
dc.contributor.author | Veciana de las Heras, Misericordia | - |
dc.contributor.author | Pedro Pérez, Jordi | - |
dc.contributor.author | Martínez Yélamos, Sergio | - |
dc.contributor.author | Sabé Fernández, Nuria | - |
dc.date.accessioned | 2021-10-21T12:52:50Z | - |
dc.date.available | 2021-10-21T12:52:50Z | - |
dc.date.issued | 2021-01-01 | - |
dc.identifier.issn | 2467-981X | - |
dc.identifier.uri | http://hdl.handle.net/2445/180720 | - |
dc.description.abstract | Introduction: Although pentavalent antimonials are no longer considered the first-line therapy for visceral leishmaniasis in the developed world, they are still used in certain geographical areas and in refractory cases. These drugs have a great number of adverse effects; however, neurological toxicity has been rarely reported. Case report: We present a 56-year-old woman who required long-term treatment with antimonial drugs due to refractory visceral leishmaniasis and presented clinically with tremor of extremities, myoclonus, gait disturbances and epileptic seizures. The EEG showed increased beta rhythms and generalized epileptogenic activity. She had a slow but favorable response after the withdrawal of antimonials and the initiation of anticonvulsant therapy. Conclusion: Severe but reversible neurological toxicity is a rare adverse effect of prolonged antimonial treatment. More EEG record data are needed to support the suspicion of a possible increase of beta rhythms in this situation. (C) 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.cnp.2021.03.008 | - |
dc.relation.ispartof | Clinical Neurophysiology Practice, 2021, vol. 6, p. 164-167 | - |
dc.relation.uri | https://doi.org/10.1016/j.cnp.2021.03.008 | - |
dc.rights | cc by-nc-nd (c) Maristany Bosch, Marta et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Leishmaniosi | - |
dc.subject.classification | Terapèutica | - |
dc.subject.classification | Toxicitat dels medicaments | - |
dc.subject.other | Leishmaniasis | - |
dc.subject.other | Therapeutics | - |
dc.subject.other | Drug toxicity | - |
dc.title | Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-10-21T08:06:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S2467981X21000214-main.pdf | 1.54 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License